US biopharma: "nearly 300 vaccines in R&D"

Article Date: 24/04/2012 06:00
US biopharma: "nearly 300 vaccines in R&D"

Vacancy Search

Quick job search

Advanced Search

Latest News

Dyax shares rocket on angioedema data

Dyax shares rocket on angioedema data

Merck Serono parnters with MMV to develop antimalarial

Merck Serono parnters with MMV to develop antimalarial

FDA OK for Teva's acute asthma inhaler

FDA OK for Teva's acute asthma inhaler

BioCryst wins $12.1m US grant to support Ebola drug

BioCryst wins $12.1m US grant to support Ebola drug

Fujifilm snaps up US human cell maker CDI for $307m

Fujifilm snaps up US human cell maker CDI for $307m

Quintiles and Quest form lab services joint venture

Quintiles and Quest form lab services joint venture

Dyax needs to deliver after surging on phase I data

The data released by Dyax on hereditary angioedema therapy DX-2930 are undoubtedly highly encouraging. They are also undoubtedly very early, having been generated in only 15 patients who...

GW tests cannabinoid drug in PhIII epilepsy trial

GW tests cannabinoid drug in PhIII epilepsy trial

Merck and Syndax form immuno-oncology pact

Merck and Syndax form immuno-oncology pact

UK new meds uptake still a "major issue"

UK new meds uptake still a "major issue"
more news